SCHEMBL25786899

SCHEMBL25786899

CCOC(=O)Cn1nnc(-c2ccccc2Nc2ccc(C(F)(P)P)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.48
▸ MAPT P10636 10/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ALDH1A1 P00352 6/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ ADRB2 P07550 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552417 0.93 MAPT (0.55) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20552400 0.88 SMN1; SMN2 (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20552250 0.87 LMNA (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25786325 0.86 XPO1 (0.46) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20552256 0.84 XPO1 (0.54) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25786906 0.82 MAPT (0.47) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25787163 0.81 KDM4E (0.52) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25787720 0.80 KMT2A (0.42) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20552310 0.79 MAPT (0.48) LMNAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL25787264 0.79 SMN1; SMN2 (0.45) LMNAMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 LMNA 2451/4885MAPT 516/4885MEN1 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback